

OSE Immunotherapeutics

Clinical update

Lusvertikimab impresses in extension period data

OSE Immunotherapeutics has presented new data for lusvertikimab in ulcerative colitis (UC), with encouraging results from the extension period of the Phase II CoTikiS trial. The key takeaway was that over 90% of patients who achieved a clinical response during the initial 10-week timeframe maintained symptomatic remission through the 24-week extension period. Furthermore, 61% of participants who did not achieve remission during induction achieved it after the extension (on the 850mg dose, the higher of the two tested doses). The safety of lusvertikimab was also confirmed across the 34-week treatment period. In our view, these results demonstrate the potential of lusvertikimab to provide durable responses for UC, thereby strengthening the candidate's data package.

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/23	2.2	(23.2)	(1.18)	0.00	N/A	N/A
12/24e	83.4	39.8	1.48	0.00	4.4	N/A
12/25e	63.5	27.0	1.23	0.00	5.3	N/A
12/26e	101.5	63.3	2.89	0.00	2.3	N/A

Note: PBT shown is normalised PBT. EPS shown is diluted EPS.

At Digestive Disease Week 2025, OSE presented its lead immuno-inflammation asset, lusvertikimab, an anti-IL-7R monoclonal antibody candidate in development for UC. The [extension data](#) were encouraging: 92% of patients who achieved remission (on either 450mg or 850mg doses of lusvertikimab) in the 10-week induction period maintained it through the 24-week extension (including 100% of patients on the 850mg dose during the induction); 61% of patients who did not achieve remission during the induction achieved it in the extension; 85% of patients on placebo during the induction achieved remission in the extension. Additionally, lusvertikimab was found to be safe and well tolerated across the 24-week extended treatment period, which, with the efficacy data, provides a robust foundation for further clinical development, in our view. We expect management to outline its next steps for this programme during 2025.

CoTikiS is a randomised, double-blind, placebo-controlled Phase II trial evaluating lusvertikimab in patients with moderate to severe UC. The study included a 10-week induction period assessing lusvertikimab at 450mg and 850mg, compared to a placebo. Top-line results were published in [July 2024](#), followed by full data in [November 2024](#) and additional details in [February/March 2025](#). Overall results have been positive, with both doses meeting the primary endpoint (improvement in [Modified Mayo Score](#) at 10 weeks) and showing statistically significant and clinically meaningful results on secondary clinical, endoscopy and histology endpoints. We note that 89% of participants who completed the 10-week induction period in CoTikiS entered the 24-week open label extension (OLE), during which all participants received the 850mg dose of lusvertikimab, and 87% completed the OLE.

For a more detailed discussion of the lusvertikimab programme and of OSE's other active proprietary and partnered programmes, we direct readers to our recently published [outlook note](#).

Healthcare

6 May 2025

Price €6.50

Market cap €151m

Net cash (including current and non-current term deposits and lease liabilities) as at 31 December 2024 €18.0m

Shares in issue 22.3m


Free float 65.0%

Code OSE

Primary exchange NXT PA

Secondary exchange N/A

Share price performance



Business description

OSE Immunotherapeutics (OSE) is based in Nantes and Paris in France and is listed on the Euronext Paris exchange. It is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies.

Analysts

Jyoti Prakash, CFA +44 (0)20 3077 5700

Arron Aatkar, PhD +44 (0)20 3077 5700

healthcare@edisongroup.com

[Edison profile page](#)

OSE Immunotherapeutics is a research client of Edison Investment Research Limited

General disclaimer and copyright

This report has been commissioned by OSE Immunotherapeutics and prepared and issued by Edison, in consideration of a fee payable by OSE Immunotherapeutics. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
